Archive ready

2023年12月期 第2四半期決算短信〔IFRS〕(連結)

https://ssl4.eir-parts.net/doc/2160/tdnet/2329433/00.pdf
May 4, 2026 at 11:40 AM JSTThe archive page, viewer, and downloads use this saved version.
May 4, 2026 at 11:40 AM JST·ssl4.eir-parts.net

The evidence pack includes HTML, screenshots, summaries, and metadata. It can be downloaded on Pro.

Saved PDF

2023年12月期 第2四半期決算短信〔IFRS〕(連結)

StartedMay 4, 2026 at 11:40 AM JST
File size0.31 MB
SHA-256d9bdaaccb2f35d38f68fd4c3c2667c73e7ce91771855944e3ee3d3393b16cdf8
About this pageAI generated

This document is the financial results report for the second quarter of the fiscal year ending December 2023 for GNI Group, Inc., covering the consolidated performance up to June 30, 2023. The report indicates a significant increase in revenue, with sales rising by 72.9% year-on-year to 14,096 million yen and operating profit increasing by 445.1% to 5,476 million yen, reflecting strong overall performance. Notably, all major subsidiaries have achieved profitability for the first time, with robust sales of the flagship product from Beijing Continent Pharmaceutical. The outlook for future performance shows no significant revisions expected.